SUPERNUS PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$2.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$2.39M.
- SUPERNUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $6.11M, a 302.77% increase from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was $1.52M, a 197.45% increase from fiscal 2022.
- SUPERNUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was $510.00K.
- SUPERNUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was -$6.53M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 7 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$2.39M 10-Q · filed 2026-08-03 | ||||||
| 2026-03-31 | -$2.39M 10-Q · filed 2026-05-05 | |||||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-03 | -$7.66M 10-Q · filed 2025-11-06 | -$8.02M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$7.66M 10-Q · filed 2026-08-03 | -$8.02M derived: sum of 3 quarters · filed 2026-08-03 | -$7.00M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | -$7.66M 10-Q · filed 2026-05-05 | -$8.02M derived: sum of 2 quarters · filed 2026-05-05 | -$7.00M derived: sum of 3 quarters · filed 2026-05-05 | -$2.65M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $660.00K derived: sum of 2 quarters · filed 2026-03-02 | $5.01M derived: sum of 3 quarters · filed 2026-03-02 | $6.11M 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.37M derived: sum of 2 quarters · filed 2025-11-06 | $6.47M 10-Q · filed 2025-11-06 | $6.67M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2024-06-30 | $4.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $5.45M 10-Q · filed 2025-08-05 | $5.65M derived: sum of 3 quarters · filed 2026-03-02 | $6.11M derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2024-03-31 | $1.09M 10-Q · filed 2025-05-06 | $1.30M derived: sum of 2 quarters · filed 2026-03-02 | $1.75M derived: sum of 3 quarters · filed 2026-03-02 | $965.00K derived: sum of 4 quarters · filed 2026-03-02 | ||||
| 2023-12-31 | $204.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $660.00K derived: sum of 2 quarters · filed 2026-03-02 | -$130.00K derived: sum of 3 quarters · filed 2026-03-02 | $1.52M 10-K · filed 2026-03-02 | ||||
| 2023-09-30 | $456.00K 10-Q · filed 2023-11-08 | -$334.00K derived: sum of 2 quarters · filed 2023-11-08 | $1.31M 10-Q · filed 2024-11-04 | -$71.00K derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | -$790.00K 10-Q · filed 2023-11-08 | $857.00K 10-Q · filed 2024-08-06 | -$527.00K derived: sum of 3 quarters · filed 2025-02-25 | -$1.01M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $1.65M 10-Q · filed 2024-05-08 | $263.00K derived: sum of 2 quarters · filed 2025-02-25 | -$223.00K derived: sum of 3 quarters · filed 2025-02-25 | -$966.00K derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$1.87M derived: sum of 2 quarters · filed 2025-02-25 | -$2.61M derived: sum of 3 quarters · filed 2025-02-25 | $510.00K 10-K · filed 2025-02-25 | -$510.00K 10-K · filed 2023-03-09 | |||
| 2022-09-30 | -$486.00K 10-Q · filed 2023-11-08 | -$1.23M derived: sum of 2 quarters · filed 2023-11-08 | $1.89M 10-Q · filed 2022-11-09 | -$774.00K derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | -$743.00K 10-Q · filed 2023-11-08 | -$1.41M 10-Q · filed 2023-08-08 | $1.41M 10-Q · filed 2022-08-08 | -$288.00K derived: sum of 3 quarters · filed 2023-11-08 | -$188.00K derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-03-31 | -$665.00K 10-Q · filed 2023-11-08 | $665.00K 10-Q · filed 2022-05-12 | $455.00K derived: sum of 2 quarters · filed 2023-11-08 | $555.00K derived: sum of 3 quarters · filed 2023-11-08 | -$8.20M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2021-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-13 | $1.22M derived: sum of 2 quarters · filed 2022-04-13 | -$7.53M derived: sum of 3 quarters · filed 2022-04-13 | -$6.53M 10-K · filed 2022-04-13 | ||||
| 2021-09-30 | $100.00K 10-Q · filed 2021-11-05 | -$8.65M derived: sum of 2 quarters · filed 2021-11-05 | -$7.65M 10-Q · filed 2021-11-05 | |||||
| 2021-06-30 | -$8.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$7.73M 10-Q · filed 2021-08-06 | ||||||
| 2021-03-31 | $1.02M 10-Q · filed 2021-05-07 | |||||||
| 2020-12-31 | $1.90M 10-Q · filed 2021-11-05 | $1.90M 10-Q · filed 2021-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |